257 related articles for article (PubMed ID: 28322234)
1. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
Heidegger I; Klocker H; Pichler R; Pircher A; Prokop W; Steiner E; Ladurner C; Comploj E; Lunacek A; Djordjevic D; Pycha A; Plas E; Horninger W; Bektic J
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):271-275. PubMed ID: 28322234
[TBL] [Abstract][Full Text] [Related]
2. Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer.
Novak V; Vesely S; Luksanová H; Prusa R; Capoun O; Fiala V; Dolejsová O; Sedlacková H; Kucera R; Stejskal J; Zalesky M; Babjuk M
BMC Urol; 2020 Sep; 20(1):144. PubMed ID: 32894109
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
[TBL] [Abstract][Full Text] [Related]
4. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
5. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
[TBL] [Abstract][Full Text] [Related]
6. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
7. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
[TBL] [Abstract][Full Text] [Related]
8. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
[TBL] [Abstract][Full Text] [Related]
9. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
10. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.
Dolejsova O; Kucera R; Fuchsova R; Topolcan O; Svobodova H; Hes O; Eret V; Pecen L; Hora M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818787377. PubMed ID: 30021484
[TBL] [Abstract][Full Text] [Related]
11. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
13. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
[TBL] [Abstract][Full Text] [Related]
15. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
16. Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy.
Chiu PK; Lai FM; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Ann Surg Oncol; 2016 Aug; 23(8):2707-14. PubMed ID: 26965697
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
20. [-2]proPSA is an early marker for prostate cancer aggressiveness.
Heidegger I; Klocker H; Steiner E; Skradski V; Ladurner M; Pichler R; Schäfer G; Horninger W; Bektic J
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):70-4. PubMed ID: 24165692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
